Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

PI3Kα H1047R mutation inhibitor

DRUG CLASS:

PI3Kα H1047R mutation inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

HR positive + PIK3CA H1047R + PIK3CA D350G + ER D538G	HER2 Negative Breast Cancer	HR positive + PIK3CA H1047R + PIK3CA D350G + ER D538G	HER2 Negative Breast Cancer	LOXO-783 Sensitive: D – Preclinical LOXO-783 Sensitive : D	LOXO-783 Sensitive: D – Preclinical LOXO-783 Sensitive : D
HR positive + PIK3CA H1047R + ER D538G	HER2 Negative Breast Cancer	HR positive + PIK3CA H1047R + ER D538G	HER2 Negative Breast Cancer	LOXO-783 Sensitive: D – Preclinical LOXO-783 Sensitive : D	LOXO-783 Sensitive: D – Preclinical LOXO-783 Sensitive : D
HR positive + PIK3CA H1047R	HER2 Negative Breast Cancer	HR positive + PIK3CA H1047R	HER2 Negative Breast Cancer	LOXO-783 Sensitive: D – Preclinical LOXO-783 Sensitive : D	LOXO-783 Sensitive: D – Preclinical LOXO-783 Sensitive : D
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	STX-478 Sensitive: D – Preclinical STX-478 Sensitive : D	STX-478 Sensitive: D – Preclinical STX-478 Sensitive : D
PIK3CA H1047R	Breast Cancer	PIK3CA H1047R	Breast Cancer	OKI-219 Sensitive: D – Preclinical OKI-219 Sensitive : D	OKI-219 Sensitive: D – Preclinical OKI-219 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib + STX-478 Sensitive: D – Preclinical palbociclib + STX-478 Sensitive : D	palbociclib + STX-478 Sensitive: D – Preclinical palbociclib + STX-478 Sensitive : D
ER positive + PIK3CA H1047R	Breast Cancer	ER positive + PIK3CA H1047R	Breast Cancer	AZD9833 + OKI-219 Sensitive: D – Preclinical AZD9833 + OKI-219 Sensitive : D	AZD9833 + OKI-219 Sensitive: D – Preclinical AZD9833 + OKI-219 Sensitive : D
ER positive + PIK3CA H1047R	Breast Cancer	ER positive + PIK3CA H1047R	Breast Cancer	elacestrant + OKI-219 Sensitive: D – Preclinical elacestrant + OKI-219 Sensitive : D	elacestrant + OKI-219 Sensitive: D – Preclinical elacestrant + OKI-219 Sensitive : D
ER positive + PIK3CA H1047R	Breast Cancer	ER positive + PIK3CA H1047R	Breast Cancer	OKI-219 Sensitive: D – Preclinical OKI-219 Sensitive : D	OKI-219 Sensitive: D – Preclinical OKI-219 Sensitive : D
ER negative + PIK3CA H1047R	Breast Cancer	ER negative + PIK3CA H1047R	Breast Cancer	tucatinib + OKI-219 Sensitive: D – Preclinical tucatinib + OKI-219 Sensitive : D	tucatinib + OKI-219 Sensitive: D – Preclinical tucatinib + OKI-219 Sensitive : D